Amredobresib

DB21566InvestigationalSmall molecule

Amredobresib is a small molecule drug. The usage of the INN stem '-bresib' in the name indicates that Amredobresib is a inhibitor of the bromodomain and extra-terminal motif (BET) family... Amredobresib is under investigation in clinical trial NCT02516553 (BI 894999 First in Human Dose Finding Study in Advanced Malignancies).

Mechanism: Pharmacologically active on Bromodomain-containing protein 4, Bromodomain-containing protein 2, and Bromodomain-containing protein 3
Curator reviewed
Formula / weight: C₂₆H₂₉N₉ · 467.581 g/mol (avg)
Code names: BI-894999

Resolves to

Compound

UNIIF6XR3O34V2CAS1610044-98-8ChEMBLCHEMBL3919831ChEBI755986PubChem76072013

Structure

InChIKeyJLUUVUUYIXBDCG-UHFFFAOYSA-NSMILESCNC1=NC(=CN2C(C)=NN=C12)C1=NC2=CC=C(C=C2N1CC1=CC=CC=C1)N1CCN(C)CC1

Targets

O60885BRD4P25440BRD2Q15059BRD3Q58F21BRDT

What you can answer from here — as of September 23, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Amredobresib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account